drugset / Trial / NCT06881810

Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

NCT06881810 ↗

Phase 2 Recruiting 98 enrolled Central Institute of Mental Health, Mannheim
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Research on schizophrenia spectrum disorders (SSD) patients with social impairment is essential for improving treatment, enhancing the lives of affected individuals, reducing stigma, and advancing our understanding of this complex psychiatric disorder. A clinical trial focusing on the improvement of social skills in SSD has the potential to transform clinical practice and support systems to better meet the needs of those living with SSD. Because of the role of oxytocin in regulating social behaviors and emotions, the investigator hypothesizes that it is beneficial in addressing the social cognition deficits observed in SSD when combined with psychosocial interventions.

Timeline

Start
2024-08-29
Primary completion
2028-03-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 80 iu Intranasal
Background Syntocinon® nasal spray Unknown — —

Indications